310 related articles for article (PubMed ID: 22748660)
21. Dendritic Cells Therapy with Cytokine-Induced Killer Cells and Activated Cytotoxic T Cells Attenuated Th2 Bias Immune Response.
Li C; Zhu D; Zhao Y; Guo Q; Sun W; Li L; Gao D; Zhao P
Immunol Invest; 2020 Jul; 49(5):522-534. PubMed ID: 31793363
[TBL] [Abstract][Full Text] [Related]
22. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
23. Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics.
Kronik N; Kogan Y; Vainstein V; Agur Z
Cancer Immunol Immunother; 2008 Mar; 57(3):425-39. PubMed ID: 17823798
[TBL] [Abstract][Full Text] [Related]
24. CAR T cells offer hope in glioblastoma.
Fyfe I
Nat Rev Neurol; 2024 Jun; 20(6):315. PubMed ID: 38745000
[No Abstract] [Full Text] [Related]
25. New perspectives in glioma immunotherapy.
Daga A; Bottino C; Castriconi R; Gangemi R; Ferrini S
Curr Pharm Des; 2011; 17(23):2439-67. PubMed ID: 21827420
[TBL] [Abstract][Full Text] [Related]
26. CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.
Hara A; Koyama-Nasu R; Takami M; Toyoda T; Aoki T; Ihara F; Kobayashi M; Hirono S; Matsutani T; Nakayama T; Iwadate Y; Motohashi S
Cancer Immunol Immunother; 2021 May; 70(5):1239-1254. PubMed ID: 33128583
[TBL] [Abstract][Full Text] [Related]
27. T-cell-associated cellular immunotherapy for lung cancer.
Li K; Zhang Q; Zhang Y; Yang J; Zheng J
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1249-58. PubMed ID: 25381064
[TBL] [Abstract][Full Text] [Related]
28. Induction of specific cytotoxic T lymphocytes against autologous brain tumor by crossreactive allo-tumor cell stimulation.
Saitoh S; Kurisaka M; Mori K; Maeda N; Fujimoto S
Jpn J Cancer Res; 1997 Mar; 88(3):289-95. PubMed ID: 9140114
[TBL] [Abstract][Full Text] [Related]
29. Targeting EGFRvIII for glioblastoma multiforme.
Yang J; Yan J; Liu B
Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
[TBL] [Abstract][Full Text] [Related]
30. Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model.
Wu Y; Deng Z; Wang H; Ma W; Zhou C; Zhang S
BMC Immunol; 2016 Sep; 17(1):29. PubMed ID: 27645787
[TBL] [Abstract][Full Text] [Related]
31. Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma.
Liu H; Chen L; Liu J; Meng H; Zhang R; Ma L; Wu L; Yu S; Shi F; Li Y; Zhang L; Wang L; Feng S; Zhang Q; Peng Y; Wu Q; Liu C; Chang X; Yang L; Uemura Y; Yu X; Liu T
Cancer Lett; 2017 Dec; 411():182-190. PubMed ID: 28947140
[TBL] [Abstract][Full Text] [Related]
32. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
33. Gammadelta T cells as immune effectors against high-grade gliomas.
Lamb LS
Immunol Res; 2009; 45(1):85-95. PubMed ID: 19711198
[TBL] [Abstract][Full Text] [Related]
34. The Safety of available immunotherapy for the treatment of glioblastoma.
Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
[TBL] [Abstract][Full Text] [Related]
35. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma.
Wood GW; Holladay FP; Turner T; Wang YY; Chiga M
J Neurooncol; 2000 Jun; 48(2):113-20. PubMed ID: 11083074
[TBL] [Abstract][Full Text] [Related]
36. Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells.
Kirkin AF; Dzhandzhugazyan KN; Guldberg P; Fang JJ; Andersen RS; Dahl C; Mortensen J; Lundby T; Wagner A; Law I; Broholm H; Madsen L; Lundell-Ek C; Gjerstorff MF; Ditzel HJ; Jensen MR; Fischer W
Nat Commun; 2018 Mar; 9(1):785. PubMed ID: 29511178
[TBL] [Abstract][Full Text] [Related]
37. [Immunotherapy in brain tumors].
De Carli E; Delion M; Rousseau A
Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
[TBL] [Abstract][Full Text] [Related]
38. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.
Dillman RO; Duma CM; Ellis RA; Cornforth AN; Schiltz PM; Sharp SL; DePriest MC
J Immunother; 2009; 32(9):914-9. PubMed ID: 19816190
[TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons.
Choi BD; Curry WT; Carter BS; Maus MV
Neurosurg Focus; 2018 Jun; 44(6):E13. PubMed ID: 29852773
[TBL] [Abstract][Full Text] [Related]
40. Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.
Riccione K; Suryadevara CM; Snyder D; Cui X; Sampson JH; Sanchez-Perez L
J Vis Exp; 2015 Feb; (96):. PubMed ID: 25741761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
